Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rejuveinix
- Development stage
- Phase 4
- Lead developer
- Reven Pharmaceuticals
- Modality
- Implantable Devices → Device-based Delivery → Drug Delivery Systems, Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Rejuveinix (RJX) is an intravenous formulation composed of a proprietary mixture of anti-oxidant and anti-inflammatory agents, primarily various vitamins including ascorbic acid (vitamin C), cyanocobalamin (vitamin B12), thiamine hydrochloride (vitamin B1), riboflavin 5' phosphate (vitamin B2), niacinamide (vitamin B3), pyridoxine hydrochloride (vitamin B6), calcium D-pantothenate, and magnesium sulfate. It is being developed as a treatment platform for sepsis and inflammatory disorders such as COVID-19-associated viral sepsis, acute respiratory distress syndrome (ARDS), multi-system inflammation, cytokine release syndrome, shock, and multi-organ failure. The drug acts through anti-oxidant and anti-inflammatory mechanisms to reduce tissue-level oxidative stress and systemic inflammation. Rejuveinix is currently in Phase II clinical trials for several indications including COVID-19-related ARDS and pneumonia[1][2][3][4][5][6][7].
- Brand names
- rejuveinix
- Other names
- RJX
02
Targets
TGFB (GARP–latent transforming growth factor beta 1 complex)IL-6 (Interleukin 6)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on rejuveinix.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rejuveinix.